Innovation in the Design of Clinical Trials for Infectious Diseases: Focusing on Patients Over Pathogens [0.03%]
传染病临床试验设计的创新:关注患者而非病原体
John H Powers rd,Robert J OConnell
John H Powers rd
Much infectious disease research focuses on the interaction of microorganisms and drugs in the laboratory, assuming biological activity of inhibiting organism growth in vitro directly translates to improving patient outcomes in the clinic. ...
Suggested Improvements to the Current East African Community Medicines Regulatory Harmonization Joint Review Process and a Proposed New Review Model for this Initiative [0.03%]
当前东非共同体药品监管协调联合审查过程的建议改进和该计划的新审查模型提案
Nancy Ngum,Chimwemwe Chamdimba,Dedith Mbonyingingo et al.
Nancy Ngum et al.
Background: In 2012, the East African Community Medicines Regulatory Harmonization (EAC-MRH) initiative was established to improve access to safe, effective, and high-quality medical products to patients in the East Afric...
Emil Scosyrev,Sigrid Behr,Devendra Jain et al.
Emil Scosyrev et al.
Disproportionality analysis is a method of safety signal detection based on quantitative analysis of spontaneous reports of adverse events. Disproportionality findings are often presented in medical publications as real-world evidence on dr...
Lorraine Danks,Boitumelo Semete-Makokotlela,Regardt Gouws et al.
Lorraine Danks et al.
Background and objectives: The inherited backlog of 16,000 medicines applications of the South African Health Products Regulatory Authority (SAHPRA) was cleared through facilitated review pathways that included reliance o...
Contraception Requirements in Early Clinical Trials: Considerations Towards an Evidence-Based Approach [0.03%]
早期临床试验中的避孕要求:向基于证据的方法的转变中的考量因素
Tatyana Dubich,Ad F Roffel
Tatyana Dubich
Enrollment of women of childbearing potential in clinical trials from early stages of drug development allows the gathering of relevant safety and pharmacokinetics data in the representative disease population. However, risk mitigation stra...
The Evolution of In-Field Medical Affairs: Introducing the Strategic Scientific Advisor [0.03%]
现场医疗事务的演变:战略科学顾问的引入
Lucía Regadera Anechina,Inmaculada Iglesias,Jorge A Marinich et al.
Lucía Regadera Anechina et al.
The evolving landscape of healthcare demands a transformation in Medical Affairs (MA) to address new challenges and opportunities. This article presents the Strategic Scientific Advisor (SSA) role as a critical innovation within our MA depa...
Peter D Stonier,Stuart A Jones
Peter D Stonier
The medicines development workforce has grown to be a multidisciplinary, interprofessional global body of broadly qualified graduate professionals working with and around the biopharmaceutical industry. To satisfy their demands of fitness f...
The Value and Importance of a Professional Ethical Code for Medicines Development: IFAPP International Ethics Framework [0.03%]
医药开发的职业伦理守则的价值和重要性——IFAPP国际伦理准则框架
Sandor Kerpel-Fronius,Alexander L Becker;Members of the IFAPP Ethics Working Group
Sandor Kerpel-Fronius
Pharmaceutical medicine professionals have to face many ethical problems during the entire life span of new medicines extending from animal studies to broad clinical practice. The primary aim of the general ethical principles governing rese...
Pricing and Impact: Understanding Sales Trends and Price-Volume Distributions of Antihypertensive Drugs in Europe, USA, and India [0.03%]
价格与影响:欧洲、美国和印度降压药销售趋势及价格-销量分布规律解析
Gautam Satheesh,Swagata Kumar Sahoo,Stephen Jan et al.
Gautam Satheesh et al.